Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
quadrivalent cell-based influenza vaccine
- Development stage
- Unknown
- Lead developer
- CSL Seqirus
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The quadrivalent cell-based influenza vaccine (QIVc) is an inactivated subunit vaccine designed to provide active immunization against four seasonal influenza virus strains: two Influenza A subtypes (H1N1 and H3N2) and two Influenza B lineages (Victoria and Yamagata). Unlike traditional influenza vaccines produced in embryonated chicken eggs, QIVc is manufactured using Madin-Darby canine kidney (MDCK) mammalian cell culture technology. This cell-based production method avoids egg-adaptive mutations that can occur during the manufacturing process, potentially resulting in a closer antigenic match to the WHO-recommended circulating strains and improved vaccine effectiveness. The vaccine contains purified hemagglutinin (HA) surface antigens from each of the four targeted strains and is indicated for use in adults and children from 6 months of age.
- Brand names
- Flucelvax QuadrivalentFlucelvax TetraSKYCellflu QIVFlucelvax
- Other names
- QIVccell-based quadrivalent influenza vaccineinfluenza vaccine (surface antigen, inactivated, prepared in cell cultures)
02
Targets
NeuraminidaseHA (Hemagglutinin)
Beyond the preview
Go deeper on quadrivalent cell-based influenza vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on quadrivalent cell-based influenza vaccine.